244 related articles for article (PubMed ID: 30668413)
21. Identification of a Potent and Broad-Spectrum Hepatitis C Virus Fusion Inhibitory Peptide from the E2 Stem Domain.
Chi X; Niu Y; Cheng M; Liu X; Feng Y; Zheng F; Fan J; Li X; Jin Q; Zhong J; Li YP; Yang W
Sci Rep; 2016 Apr; 6():25224. PubMed ID: 27121372
[TBL] [Abstract][Full Text] [Related]
22. Chlorcyclizine Inhibits Viral Fusion of Hepatitis C Virus Entry by Directly Targeting HCV Envelope Glycoprotein 1.
Hu Z; Rolt A; Hu X; Ma CD; Le DJ; Park SB; Houghton M; Southall N; Anderson DE; Talley DC; Lloyd JR; Marugan JC; Liang TJ
Cell Chem Biol; 2020 Jul; 27(7):780-792.e5. PubMed ID: 32386595
[TBL] [Abstract][Full Text] [Related]
23. Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry.
Brown KS; Keogh MJ; Owsianka AM; Adair R; Patel AH; Arnold JN; Ball JK; Sim RB; Tarr AW; Hickling TP
Protein Cell; 2010 Jul; 1(7):664-74. PubMed ID: 21203938
[TBL] [Abstract][Full Text] [Related]
24. A Novel Inhibitor IDPP Interferes with Entry and Egress of HCV by Targeting Glycoprotein E1 in a Genotype-Specific Manner.
Lee M; Yang J; Jo E; Lee JY; Kim HY; Bartenschlager R; Shin EC; Bae YS; Windisch MP
Sci Rep; 2017 Mar; 7():44676. PubMed ID: 28333153
[TBL] [Abstract][Full Text] [Related]
25. In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.
Mailly L; Wrensch F; Heydmann L; Fauvelle C; Brignon N; Zeisel MB; Pessaux P; Keck ZY; Schuster C; Fuerst TR; Foung SKH; Baumert TF
Antiviral Res; 2019 Feb; 162():136-141. PubMed ID: 30599173
[TBL] [Abstract][Full Text] [Related]
26. Entry inhibitors: New advances in HCV treatment.
Qian XJ; Zhu YZ; Zhao P; Qi ZT
Emerg Microbes Infect; 2016 Jan; 5(1):e3. PubMed ID: 26733381
[TBL] [Abstract][Full Text] [Related]
27. Micrococcin P1, a naturally occurring macrocyclic peptide inhibiting hepatitis C virus entry in a pan-genotypic manner.
Lee M; Yang J; Park S; Jo E; Kim HY; Bae YS; Windisch MP
Antiviral Res; 2016 Aug; 132():287-95. PubMed ID: 27387825
[TBL] [Abstract][Full Text] [Related]
28. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
J Virol; 2019 May; 93(10):. PubMed ID: 30842319
[TBL] [Abstract][Full Text] [Related]
29. A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes.
Haid S; Novodomská A; Gentzsch J; Grethe C; Geuenich S; Bankwitz D; Chhatwal P; Jannack B; Hennebelle T; Bailleul F; Keppler OT; Poenisch M; Bartenschlager R; Hernandez C; Lemasson M; Rosenberg AR; Wong-Staal F; Davioud-Charvet E; Pietschmann T
Gastroenterology; 2012 Jul; 143(1):213-22.e5. PubMed ID: 22465429
[TBL] [Abstract][Full Text] [Related]
30. Identification of peptides that bind hepatitis C virus envelope protein E2 and inhibit viral cellular entry from a phage-display peptide library.
Lü X; Yao M; Zhang JM; Yang J; Lei YF; Huang XJ; Jia ZS; Ma L; Lan HY; Xu ZK; Yin W
Int J Mol Med; 2014 May; 33(5):1312-8. PubMed ID: 24573486
[TBL] [Abstract][Full Text] [Related]
31. 5-Oxo-1-[(2,3,6,7-tetramethoxy-9-phenanthrenyl)methyl]-L-proline Inhibits Hepatitis C Virus Entry.
Nguyen LP; Park C; Luong TTD; Park EM; Choi DH; Han KM; Mai HN; Nguyen HC; Lim YS; Hwang SB
Sci Rep; 2019 May; 9(1):7288. PubMed ID: 31086268
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization.
Schvoerer E; Moenne-Loccoz R; Murray JM; Velay A; Turek M; Fofana I; Fafi-Kremer S; Erba AC; Habersetzer F; Doffoël M; Gut JP; Donlin MJ; Tavis JE; Zeisel MB; Stoll-Keller F; Baumert TF
J Infect Dis; 2013 Apr; 207(8):1306-15. PubMed ID: 23335805
[TBL] [Abstract][Full Text] [Related]
33. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans.
Helle F; Wychowski C; Vu-Dac N; Gustafson KR; Voisset C; Dubuisson J
J Biol Chem; 2006 Sep; 281(35):25177-83. PubMed ID: 16809348
[TBL] [Abstract][Full Text] [Related]
34. Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein.
Al Olaby RR; Cocquerel L; Zemla A; Saas L; Dubuisson J; Vielmetter J; Marcotrigiano J; Khan AG; Vences Catalan F; Perryman AL; Freundlich JS; Forli S; Levy S; Balhorn R; Azzazy HM
PLoS One; 2014; 9(10):e111333. PubMed ID: 25357246
[TBL] [Abstract][Full Text] [Related]
35. Specialization of Hepatitis C Virus Envelope Glycoproteins for B Lymphocytes in Chronically Infected Patients.
Douam F; Bobay LM; Maurin G; Fresquet J; Calland N; Maisse C; Durand T; Cosset FL; Féray C; Lavillette D
J Virol; 2016 Jan; 90(2):992-1008. PubMed ID: 26537674
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.
Wasilewski LN; Ray SC; Bailey JR
J Gen Virol; 2016 Nov; 97(11):2883-2893. PubMed ID: 27667373
[TBL] [Abstract][Full Text] [Related]
37. Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry.
Matsumura T; Hu Z; Kato T; Dreux M; Zhang YY; Imamura M; Hiraga N; Juteau JM; Cosset FL; Chayama K; Vaillant A; Liang TJ
Gastroenterology; 2009 Aug; 137(2):673-81. PubMed ID: 19394333
[TBL] [Abstract][Full Text] [Related]
38. Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly.
Haddad JG; Rouillé Y; Hanoulle X; Descamps V; Hamze M; Dabboussi F; Baumert TF; Duverlie G; Lavie M; Dubuisson J
J Virol; 2017 Apr; 91(8):. PubMed ID: 28179528
[TBL] [Abstract][Full Text] [Related]
39. [Research on hepatitis C virus entry inhibitor].
Zeng Wenting ; Lu X; Wang J; Jin X; Zhu J
Bing Du Xue Bao; 2015 Jan; 31(1):97-105. PubMed ID: 25997338
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 contain reduced cysteine residues essential for virus entry.
Fraser J; Boo I; Poumbourios P; Drummer HE
J Biol Chem; 2011 Sep; 286(37):31984-92. PubMed ID: 21768113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
